{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:17:23Z","timestamp":1781803043651,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16dm0107056h0001"],"award-info":[{"award-number":["16dm0107056h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jbior.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T03:05:08Z","timestamp":1483671908000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-5943","authenticated-orcid":false,"given":"Taisuke","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2017.01.001_bib1","first-page":"1","article-title":"Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies","author":"Amanatkar","year":"2016","journal-title":"Expert Rev. Neurother."},{"issue":"7568","key":"10.1016\/j.jbior.2017.01.001_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature14892","article-title":"An atomic structure of human gamma-secretase","volume":"525","author":"Bai","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jbior.2017.01.001_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jbior.2017.01.001_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","article-title":"Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42\/1-40 ratio in\u00a0vitro and in\u00a0vivo","volume":"17","author":"Borchelt","year":"1996","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.jbior.2017.01.001_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/85064","article-title":"BACE1 is the major beta-secretase for generation of Abeta peptides by neurons","volume":"4","author":"Cai","year":"2001","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.jbior.2017.01.001_bib6","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/emboj.2012.79","article-title":"The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease","volume":"31","author":"Chavez-Gutierrez","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.jbior.2017.01.001_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fneur.2013.00122","article-title":"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease","volume":"4","author":"Chesser","year":"2013","journal-title":"Front. Neurol."},{"issue":"19","key":"10.1016\/j.jbior.2017.01.001_bib8","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/bi400377p","article-title":"Development and mechanism of gamma-secretase modulators for Alzheimer's disease","volume":"52","author":"Crump","year":"2013","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.jbior.2017.01.001_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat. reviews. Neurol."},{"issue":"3","key":"10.1016\/j.jbior.2017.01.001_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clinbiochem.2003.11.012","article-title":"Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia","volume":"37","author":"Diamandis","year":"2004","journal-title":"Clin. Biochem."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A\u00a0phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jbior.2017.01.001_bib13","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in\u00a0vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jbior.2017.01.001_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.expneurol.2009.09.013","article-title":"Cholesterol and statins in Alzheimer's disease: current controversies","volume":"223","author":"Fonseca","year":"2010","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-0102(02)00015-9","article-title":"Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology","volume":"43","author":"Fukami","year":"2002","journal-title":"Neurosci. Res."},{"issue":"6","key":"10.1016\/j.jbior.2017.01.001_bib16","first-page":"1633","article-title":"Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease","volume":"152","author":"Funato","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1074\/jbc.M114.629287","article-title":"Suppressor mutations for presenilin 1 familial alzheimer disease mutants modulate gamma-secretase activities","volume":"291","author":"Futai","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"issue":"19","key":"10.1016\/j.jbior.2017.01.001_bib18","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer's disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem. Soc. Rev."},{"issue":"6248","key":"10.1016\/j.jbior.2017.01.001_bib19","doi-asserted-by":"crossref","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"issue":"5534","key":"10.1016\/j.jbior.2017.01.001_bib20","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils","volume":"293","author":"Gotz","year":"2001","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jbior.2017.01.001_bib21","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1074\/mcp.M115.050724","article-title":"The human tau interactome: binding to the ribonucleoproteome, and impaired binding of the proline-to-leucine mutant at position 301 (P301L) to chaperones and the proteasome","volume":"14","author":"Gunawardana","year":"2015","journal-title":"Molecular cell. Proteom.: MCP"},{"issue":"11","key":"10.1016\/j.jbior.2017.01.001_bib22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/nm783","article-title":"Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease","volume":"8","author":"Hock","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib23","first-page":"15","article-title":"Tau and neurodegenerative disease: the story so far. Nature reviews","volume":"12","author":"Iqbal","year":"2016","journal-title":"Neurology"},{"issue":"5521","key":"10.1016\/j.jbior.2017.01.001_bib24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","article-title":"Metabolic regulation of brain Abeta by neprilysin","volume":"292","author":"Iwata","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jbior.2017.01.001_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/72237","article-title":"Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition","volume":"6","author":"Iwata","year":"2000","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)","volume":"13","author":"Iwatsubo","year":"1994","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet. Neurol."},{"issue":"7409","key":"10.1016\/j.jbior.2017.01.001_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A\u00a0mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jbior.2017.01.001_bib29","first-page":"3775","article-title":"Steroids as gamma-secretase modulators","volume":"27","author":"Jung","year":"2013","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"9","key":"10.1016\/j.jbior.2017.01.001_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"363","key":"10.1016\/j.jbior.2017.01.001_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.jbior.2017.01.001_bib32","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2010.167","article-title":"ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons","volume":"29","author":"Kuhn","year":"2010","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.jbior.2017.01.001_bib33","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in\u00a0vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"issue":"5534","key":"10.1016\/j.jbior.2017.01.001_bib34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jbior.2017.01.001_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nat. Neurosci."},{"issue":"6012","key":"10.1016\/j.jbior.2017.01.001_bib36","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jbior.2017.01.001_bib37","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1073\/pnas.1031520100","article-title":"Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in\u00a0vivo","volume":"100","author":"Miller","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.jbior.2017.01.001_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd.2016.176","article-title":"Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbior.2017.01.001_bib39","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","author":"Novak","year":"2016","journal-title":"Lancet. Neurol."},{"issue":"23","key":"10.1016\/j.jbior.2017.01.001_bib40","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1038\/emboj.2011.372","article-title":"Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1","volume":"30","author":"Ohki","year":"2011","journal-title":"EMBO J."},{"issue":"33","key":"10.1016\/j.jbior.2017.01.001_bib41","doi-asserted-by":"crossref","first-page":"22529","DOI":"10.1074\/jbc.M801925200","article-title":"Direct and potent regulation of gamma-secretase by its lipid microenvironment","volume":"283","author":"Osenkowski","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.jbior.2017.01.001_bib42","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1074\/jbc.272.10.6641","article-title":"Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells","volume":"272","author":"Qiu","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"issue":"12","key":"10.1016\/j.jbior.2017.01.001_bib43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet. Neurol."},{"issue":"5825","key":"10.1016\/j.jbior.2017.01.001_bib44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","article-title":"APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy","volume":"38","author":"Rovelet-Lecrux","year":"2006","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.jbior.2017.01.001_bib46","doi-asserted-by":"crossref","first-page":"a006379","DOI":"10.1101\/cshperspect.a006379","article-title":"Proteolytic degradation of amyloid beta-protein","volume":"2","author":"Saido","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7","key":"10.1016\/j.jbior.2017.01.001_bib47","first-page":"321","article-title":"Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Proceedings of the Japan Academy","volume":"89","author":"Saido","year":"2013","journal-title":"Ser. B, Phys. Biol. Sci."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nm1206","article-title":"Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation","volume":"11","author":"Saito","year":"2005","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jbior.2017.01.001_bib50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"7618","key":"10.1016\/j.jbior.2017.01.001_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2017.01.001_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbior.2014.10.002","article-title":"Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes","volume":"57","author":"Shamseddine","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"6534","key":"10.1016\/j.jbior.2017.01.001_bib53","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","article-title":"Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease","volume":"375","author":"Sherrington","year":"1995","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jbior.2017.01.001_bib54","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J.\u00a0Clin. Investigation"},{"issue":"1","key":"10.1016\/j.jbior.2017.01.001_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/hsz-2013-0230","article-title":"Amyloid beta peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Abeta-mediated toxicity in\u00a0vitro","volume":"395","author":"Shropshire","year":"2014","journal-title":"Biol. Chem."},{"issue":"3","key":"10.1016\/j.jbior.2017.01.001_bib56","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer's disease: implications for prevention trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.jbior.2017.01.001_bib57","doi-asserted-by":"crossref","first-page":"e64050","DOI":"10.1371\/journal.pone.0064050","article-title":"FTY720\/fingolimod, a sphingosine analogue, reduces amyloid-beta production in neurons","volume":"8","author":"Takasugi","year":"2013","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.jbior.2017.01.001_bib58","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2014.12.087","article-title":"Synthetic ceramide analogues increase amyloid-beta 42 production by modulating gamma-secretase activity","volume":"457","author":"Takasugi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6930","key":"10.1016\/j.jbior.2017.01.001_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature01506","article-title":"The role of presenilin cofactors in the gamma-secretase complex","volume":"422","author":"Takasugi","year":"2003","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.jbior.2017.01.001_bib60","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1073\/pnas.1402171111","article-title":"Allosteric regulation of gamma-secretase activity by a phenylimidazole-type gamma-secretase modulator","volume":"111","author":"Takeo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jb\/mvu049","article-title":"Molecular mechanism of intramembrane proteolysis by gamma-secretase","volume":"156","author":"Tomita","year":"2014","journal-title":"J.\u00a0Biochem."},{"issue":"5","key":"10.1016\/j.jbior.2017.01.001_bib62","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1073\/pnas.94.5.2025","article-title":"The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue","volume":"94","author":"Tomita","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"36","key":"10.1016\/j.jbior.2017.01.001_bib63","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","article-title":"Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta","volume":"29","author":"Yamada","year":"2009","journal-title":"J.\u00a0Neurosci. : Official J. Soc. Neurosci."},{"key":"10.1016\/j.jbior.2017.01.001_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40035-016-0061-5","article-title":"Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs","volume":"5","author":"Yan","year":"2016","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.jbior.2017.01.001_bib65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the beta secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.jbior.2017.01.001_bib66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jbior.2015.11.003","article-title":"Primary phospholipase C and brain disorders","volume":"61","author":"Yang","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2017.01.001_bib67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jbior.2013.09.007","article-title":"O-GlcNAcylation in cellular functions and human diseases","volume":"54","author":"Yang","year":"2014","journal-title":"Adv. Biol. Regul."},{"issue":"4","key":"10.1016\/j.jbior.2017.01.001_bib68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.jbior.2017.01.001_bib69","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/nm.4199","article-title":"Caspase-2 cleavage of tau reversibly impairs memory","volume":"22","author":"Zhao","year":"2016","journal-title":"Nat. Med."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492616300665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492616300665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:52:15Z","timestamp":1762606335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492616300665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":69,"alternative-id":["S2212492616300665"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2017.01.001","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}